Volrubigene Ralaparvovec

N/A

Report date: 2023/10/26 16:14:58

Base Information

Drug NameVolrubigene Ralaparvovec
Drug Alias NameCrigler- Najjar-Syndrome-gene-therapy-AudentesAAV-gene-therapy-AudentesAAV-UGT1A1AT-342
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV8 vector
Mechanisms of ActionGene transference
TargetsNot applicable
Therapy Area/IndicationsCrigler-Najjar Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAudentes Therapeutics IncUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAudentes Therapeutics IncUniversity Of Pennsylvania
Active IndicationsN/A
Inactive IndicationsCrigler-Najjar Syndrome

Other Information

ATC CodeN/A
Related LinksN/A